Floatz logo

RAMIFENTANYL

Chronic Pain Syndrome

Beijing Tiantan HospitalSmall moleculePhase 4 / ApprovedActive
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
66/ 100
Competitive Position
73/ 100

Competitive context

90 Active assets in the Chronic Pain Syndrome cohort.

Asset / SponsorPhaseRating
(±)-Tramadol
EMS
Phase 4BBB
Lidocaine
National and Kapodistrian University of Athens
Phase 4BBB
METHADONE
Cari Health Inc.
Phase 4BBB
FENTANYL
Aga Khan University
Phase 4BBB
NEPENTHE
Bursa City Hospital
Phase 4BBB

View all 50 →

Same molecule, other indications

RAMIFENTANYL is also rated in:

cardiovascular disorderActive
BBB
Indicative · Phase 4
73 / 100
View asset →
morbid obesityActive
BBB
Indicative · Phase 4
73 / 100
View asset →
substance-related disorderDormant
BB
Indicative · Phase 4
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →